GSK Wins FDA Approval for Utebzi, First Oral Carbapenem Antibiotic

Strategic News Watch — June 18, 2026

GSK’s Utebzi became the first oral carbapenem antibiotic to win FDA approval, while Biogen agreed to pay up to $1 billion for immunology biotech RayThera and Eli Lilly’s retatrutide delivered unprecedented Phase III weight-loss data at ADA 2026.

Today’s top developments:

GSK won FDA approval for Utebzi, the first oral carbapenem antibiotic (pharmaphorum)
Biogen agreed to acquire immunology biotech RayThera for up to $1 billion (PharmExec)
Eli Lilly’s retatrutide posted unprecedented Phase III TRIUMPH-1 weight-loss results at ADA 2026 (Pharmaceutical Technology)
LG AI Research and D&D Pharmatech partnered to develop next-generation oral peptide drugs (Pharmaceutical Technology)
Pfizer CFO Dave Denton will step down to take a role outside the pharmaceutical industry (BioPharma Dive)
Cardiovascular biotech Kardigan raised $400 million in an upsized IPO (pharmaphorum)
Cellares and Ori lead automated cell therapy manufacturing as 23 companies raised $1.1 billion (Fierce Pharma)
PharmaVoice analysis outlines how drugmakers can prepare for a rebounding M&A market (PharmaVoice)

What to Watch

Obesity Market Competition — Lilly’s retatrutide TRIUMPH-1 data could shift prescribing patterns and payer coverage decisions if weight loss margins exceed existing GLP-1 therapies, potentially pressuring Novo Nordisk’s Wegovy pricing.
Cell Therapy Manufacturing Economics — With over $1 billion flowing into automation platforms, watch for pricing pressure on traditional CDMO services and potential M&A as manufacturers seek to secure automation capacity ahead of expected CAR-T approval waves.
Pfizer Leadership Transition — Denton’s CFO departure amid ongoing restructuring could signal board-level strategic disagreements; monitor Q2 earnings guidance and any accelerated asset divestiture announcements.
Oral Carbapenem Utilization — GSK’s Utebzi approval could face hospital formulary resistance given entrenched IV carbapenem protocols; payer coverage decisions and CDC antimicrobial stewardship guidance will determine commercial uptake trajectory.

This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.

Related Stories

Mahzi Lets Rare-Disease Families Invest in Its Gene Therapy

FDA Posts 14 New Rejection Letters Just Days After Confirming a Pause

Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen Failure